使用感染性人乳头瘤病毒/棉尾兔乳头瘤病毒嵌合乳头瘤病毒颗粒在体内测试人乳头瘤病毒（HPV）衣壳疫苗的临床前模型。
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
作者信息
Mejia Andres F, Culp Timothy D, Cladel Nancy M, Balogh Karla K, Budgeon Lynn R, Buck Christopher B, Christensen Neil D
机构信息
Gittlen Cancer Research Foundation, Pennsylvania State University College of Medicine, 500 University Dr., Hershey, PA 17033-2390, USA.
出版信息
J Virol. 2006 Dec;80(24):12393-7. doi: 10.1128/JVI.01583-06. Epub 2006 Sep 27.
Abstract
A human papillomavirus (HPV) vaccine consisting of virus-like particles (VLPs) was recently approved for human use. It is generally assumed that VLP vaccines protect by inducing type-specific neutralizing antibodies. Preclinical animal models cannot be used to test for protection against HPV infections due to species restriction. We developed a model using chimeric HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of HPV VLP vaccines in rabbits. Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles. Strong type-specific protection was observed, demonstrating the potential application of this approach.
摘要
一种由病毒样颗粒（VLP）组成的人乳头瘤病毒（HPV）疫苗最近被批准用于人类。一般认为，VLP疫苗通过诱导型特异性中和抗体来提供保护。由于物种限制，临床前动物模型不能用于测试针对HPV感染的保护作用。我们开发了一种使用嵌合HPV衣壳/棉尾兔乳头瘤病毒（CRPV）基因组颗粒的模型，以允许在兔体内直接测试HPV VLP疫苗。用CRPV、16型HPV（HPV-16）或HPV-11 VLP疫苗接种的动物，分别用同源（CRPV衣壳）和嵌合（HPV-16衣壳）颗粒进行攻击。观察到了强烈的型特异性保护作用，证明了该方法的潜在应用价值。
相似文献
1
Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
J Virol. 2006 Dec;80(24):12393-7. doi: 10.1128/JVI.01583-06. Epub 2006 Sep 27.
2
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
3
Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes.
Vaccine. 2006 Jun 29;24(26):5516-25. doi: 10.1016/j.vaccine.2006.04.058. Epub 2006 May 6.
4
The seroprevalence of IgG antibodies to human papillomavirus (HPV) types HPV-16, HPV-18, and HPV-11 capsid-antigens in mothers and their children.
J Med Virol. 2007 Sep;79(9):1370-4. doi: 10.1002/jmv.20874.
5
Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Vaccine. 2006 Aug 31;24 Suppl 3:S3/106-13. doi: 10.1016/j.vaccine.2006.05.110. Epub 2006 Jun 23.
6
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.
J Virol. 1995 Jun;69(6):3959-63. doi: 10.1128/JVI.69.6.3959-3963.1995.
7
Prophylactic DNA immunization against multiple papillomavirus types.
Vaccine. 2007 Jun 6;25(23):4540-53. doi: 10.1016/j.vaccine.2007.04.001. Epub 2007 Apr 20.
8
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
Vaccine. 2007 Jun 21;25(26):4931-9. doi: 10.1016/j.vaccine.2007.03.049. Epub 2007 Apr 20.
9
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Cancer Res. 2006 Dec 1;66(23):11120-4. doi: 10.1158/0008-5472.CAN-06-2560.
10
Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge.
Vaccine. 2006 Mar 15;24(12):2087-93. doi: 10.1016/j.vaccine.2005.11.029. Epub 2005 Nov 28.
引用本文的文献
1
Challenges and Opportunities for Data Science in Women's Health.
Annu Rev Biomed Data Sci. 2023 Aug 10;6:23-45. doi: 10.1146/annurev-biodatasci-020722-105958. Epub 2023 Apr 11.
2
Pseudotyped Virus for Papillomavirus.
Adv Exp Med Biol. 2023;1407:85-103. doi: 10.1007/978-981-99-0113-5_5.
3
Modeling HPV-Associated Disease and Cancer Using the Cottontail Rabbit Papillomavirus.
Viruses. 2022 Sep 4;14(9):1964. doi: 10.3390/v14091964.
4
High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility.
Sci Rep. 2021 Feb 10;11(1):3498. doi: 10.1038/s41598-021-83076-5.
5
Opportunities and challenges for human papillomavirus vaccination in cancer.
Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2.
6
High-Resolution Structure Analysis of Antibody V5 and U4 Conformational Epitopes on Human Papillomavirus 16.
Viruses. 2017 Dec 6;9(12):374. doi: 10.3390/v9120374.
7
Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.
Viruses. 2017 Nov 10;9(11):336. doi: 10.3390/v9110336.
8
Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.
Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.
9
Recent advances in preclinical model systems for papillomaviruses.
Virus Res. 2017 Mar 2;231:108-118. doi: 10.1016/j.virusres.2016.12.004. Epub 2016 Dec 9.
10
Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
J Virol. 2016 Jun 24;90(14):6314-25. doi: 10.1128/JVI.00449-16. Print 2016 Jul 15.
本文引用的文献
1
Papillomavirus particles assembled in 293TT cells are infectious in vivo.
J Virol. 2006 Nov;80(22):11381-4. doi: 10.1128/JVI.01328-06. Epub 2006 Aug 30.
2
Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation.
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9311-6. doi: 10.1073/pnas.0504020102. Epub 2005 Jun 15.
3
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
Virology. 2005 Jul 5;337(2):365-72. doi: 10.1016/j.virol.2005.04.011.
4
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.
Lancet Oncol. 2005 May;6(5):271-8. doi: 10.1016/S1470-2045(05)70101-7.
5
Global cancer statistics, 2002.
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. doi: 10.3322/canjclin.55.2.74.
6
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
Lancet. 2004;364(9447):1757-65. doi: 10.1016/S0140-6736(04)17398-4.
7
Against which human papillomavirus types shall we vaccinate and screen? The international perspective.
Int J Cancer. 2004 Aug 20;111(2):278-85. doi: 10.1002/ijc.20244.
8
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.
Virology. 2004 Apr 10;321(2):205-16. doi: 10.1016/j.virol.2003.12.027.
9
Efficient intracellular assembly of papillomaviral vectors.
J Virol. 2004 Jan;78(2):751-7. doi: 10.1128/jvi.78.2.751-757.2004.
10
A controlled trial of a human papillomavirus type 16 vaccine.
N Engl J Med. 2002 Nov 21;347(21):1645-51. doi: 10.1056/NEJMoa020586.
Zotero 插件